Programme 2020

18.30 - 20.00

Welcome Reception

08.00 - 08:30

Meeting Registration

08.30 - 08.45

Introduction & Meeting Objectives
John Gribben & Anas Younes

08.45 - 10.15

Session I: T-cell Lymphomas

Chair: Laurence de Leval

• EBV-associated lymphoproliferations:
  • Pathobiology and Spectrum; Elaine Jaffe
  • Clinical Perspective; Arnaud Jaccard
• Biology clinics and management of breast implant associated ALCLs:
  • Experience from the French registry; Corinne Haioun
• Update and perspectives for epigenetic modifier therapy in PTCLs; Owen O’Connor

Roundtable Discussion

10.45 - 12.15

Session II: Hodgkin’s Lymphoma

Chair: Anas Younes

• Early stage; Peter Johnson
• Advanced stage; Andreas Engert
• Relapse disease; Alex Herrera
• Future directions; Anas Younes

Roundtable Discussion

13.15 - 14.45

Session III: Keynote Address – Mantle Cell Lymphoma

Chair & Introduction: Elaine Jaffe

Keynote Speaker: Elias Campo

Roundtable Discussion

15.00 - 16.30

Session IV: Immunotherapy / Microenvironment

Chair: David Maloney

• Targeting the Immune Microenvironment; Massimo Di Nicola
• CBT in specific lymphoma subtypes; Stephan Ansell
• Biomarkers that predict for sensitivity to CBT; TBC
• IMiDs in combination; TBC
• Checkpoint inhibitors; TBC

08.30 - 10.45

Session V: Novel Therapies

Chairs: Laurie Sehn & Franck Morschhauser

• ADCs:
  • Polatuzumab vedotin; Laurie Sehn
  • Loncastuximab tesirine; Brad Kahl
  • ADCT-301 camidanlumab tesirine; Graham Collins
• CD20 / CD3 bispecific antibodies: How to choose?
  • Mosunetuzumab; Stephen Schuster
  • CD20 TCB; Franck Morschhauser
  • REGN1979; Rajat Bannerji
  • DuoBody-CD3xCD20 (GEN3013); Tuna Mutis
• Oral PI3K delta inhibitors in lymphoma; Owen O’Connor

e-break

• Novel BTK inhibitors: how to choose?
  • Zanubrutinib; Michael Wang
  • Acalabrutinib; Tom Witzig
  • Loxo0305; Anthony Mato
  • Tirabrutinib; Kensei Tobinai
• SINE inhibitors: Selinexor; Sundar Jagannath
• Tafasitamab (MOR208) in DLBCL; Gilles Salles

Roundtable Discussion

11.00 - 12.45

Session VI: Clinical Trial Design

Chairs: Andy Zelenetz & Stephen Ansell

Roundtable Discussion

13.30 - 15.30

Session VII: T-cell Therapies for Lymphoma

Chairs: Cath Bollard & Jeremy Abramson 

• CD19-CAR-T cells:
  • Lisocabtagene maraleucel (liso-cel) in DLBCL; Jeremy Abramson
  • Axicabtagene ciloleucel (axi-cel) in DLBCL; Sattva Neelapu
• Antigen-specific T-cell overview; Cath Bollard
• CD30-CAR-T cells; Barbara Savoldo
• CD5 and/or 7 CAR-T cell; Max Mamonkin
• Third party EBV T-cells; Susan Prockop

Roundtable Discussion

15.30

Final Meeting Summary & Conclusions
iwNHL Committee